) --

Keryx Biopharmaceuticals



) hit a new 52-week low Friday as it is currently trading at $2.55, below its previous 52-week low of $2.58 with 329,693 shares traded as of 12:09 p.m. ET. Average volume has been 1.5 million shares over the past 30 days.

Keryx has a market cap of $196 million and is part of the

health care

sector and


industry. Shares are down 42.6% year to date as of the close of trading on Wednesday.

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease.

  • Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Keryx as a


. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, poor profit margins and generally disappointing historical performance in the stock itself. You can view the full

Keryx Ratings Report


See all

52-week low stocks

or get investment ideas from our

investment research center